Considering their high response rate to chemotherapy and poor survival, ER+/PR-/HER-2- patients with high proliferation rates displayed biological behaviors similar to those of patients with triple-negative breast cancer [12]. Here, ESR1 is linked to triple-negative breast carcinoma.